Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Food & drink

Imperial Brands gets boost as JPMorgan Cazenove upgrades to ‘overweight’ from ‘neutral’

The upgrade came as the US bank nudged down its target price for the firm to 1,650p from 1,700p, albeit with the shares trading currently at 1,298p

Imperial Brands PLC (LON:IMB) got a boost on Friday as JPMorgan Cazenove upgraded its rating for the cigarette maker to ‘overweight’ from ‘neutral’.

The upgrade came as the US investment bank nudged down its target price for the FTSE 100-listed firm to 1,650p from 1,700p, albeit with the shares trading currently at 1,298p, up 2.2% on Thursday’s close.

READ: Imperial Brands chief financial officer to retire

In a note to clients, JPMorgan’s analysts said: “We see current valuation as pricing in severe downside risks, leaving risk/reward tilted strongly to the upside following the dividend cut this May.”

They added: “Supported by its robust FCF (19% 21e FCF yield), we see IMB’s c50% payout ratio as sustainable with a further £1bn+ p.a. available for cash returns or M&A from FY23e in our base case. We forecast MSD MT EPS CAGR (vs tobacco peers and wider EU Staples at M-HSD) driven by more targeted NGP investment and continued tobacco margin expansion.”

The analysts also noted: “With IMB’s valuation discounting its listless direction, the arrival of new (external) CEO Stefan Bomhard provides free optionality should he show competency and his new perspective can begin to re-build investor confidence.”

“Our FY20e/21e EPS changes by 0%/4% as incorporate improved US tobacco growth and new NGP forecasts, including £200m of impairments in H220e. We lower our Dec-21 price target to £16.50 (30% upside) underpinned by our new DCF-based valuation methodology,” they concluded.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK